PARP2 and neoplasm: Together, our data indicate that PARP2 deficiency suppresses tumor onset and lung metastasis yet increases bone metastasis without affecting primary tumor growth, suggesting that the microenvironment in bone is specifically responsible for the olaparib induction of bone metastasis.